Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.30 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | F2R | P25116 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10121258 | 0.84 | CHRNA7 (0.34) | CHRNA7ADORA2A | |
| SCHEMBL10155111 | 0.81 | KDM1A (0.44) | MCHR1NOS1NOS3KDM1AMAOA | |
| SCHEMBL22361447 | 0.76 | MCHR1 (0.36) | MCHR1NOS1NOS3KDM1AMAOA | |
| SCHEMBL4051420 | 0.74 | CCR1 (0.40) | CHRNA7ADORA2ANOS1 | |
| SCHEMBL23106908 | 0.74 | CCNT1 (0.34) | CHRNA7ADORA2A | |
| SCHEMBL1581851 | 0.72 | KCNH2 (0.36) | CHRNA7ADORA2ANOS1 | |
| SCHEMBL31481285 | 0.72 | KCNH2 (0.36) | CHRNA7ADORA2ANOS1 | |
| SCHEMBL17828026 | 0.72 | ADORA2A (0.43) | ADORA2ANOS1KDM1AMAOAMAOB | |
| SCHEMBL20281655 | 0.71 | HRH4 (0.39) | — | |
| SCHEMBL3511384 | 0.71 | IRAK4 (0.39) | CHRNA7ADORA2ANOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | CHRNA7 4768/4885ADORA2A 1879/4885MCHR1 4819/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CHRNA7 4756/4885ADORA2A 745/4885MCHR1 4608/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | CHRNA7 4768/4885ADORA2A 1879/4885MCHR1 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.